Short Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Declines By 10.2%

Appili Therapeutics Inc. (OTCMKTS:APLIF – Get Rating) saw a significant decline in short interest in December. As of December 30th, there was short interest totalling 60,600 shares, a decline of 10.2% from the December 15th total of 67,500 shares. Based on an average trading volume of 84,800 shares, the short-interest ratio is presently 0.7 days.

Appili Therapeutics Trading Up 53.5 %

Shares of Appili Therapeutics stock opened at $0.07 on Monday. The business’s 50-day moving average price is $0.04 and its 200-day moving average price is $0.04. The firm has a market capitalization of $4.70 million, a PE ratio of -0.51 and a beta of -0.65. Appili Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.13.

Appili Therapeutics (OTCMKTS:APLIF – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.01. The business had revenue of $0.01 million during the quarter. As a group, analysts predict that Appili Therapeutics will post -0.06 earnings per share for the current fiscal year.

About Appili Therapeutics

(Get Rating)

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.